Next Article in Journal
Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging
Next Article in Special Issue
Design, Synthesis and Anticandidal Evaluation of Indazole and Pyrazole Derivatives
Previous Article in Journal
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
Previous Article in Special Issue
Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources
Review

Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience

1
German Center for Infections in Obstetrics and Gynaecology, Heusnerstrasse 40, D-42283 Wuppertal, Germany
2
Bayer Consumer Care AG, Peter Merian-Strasse 84, CH-4002 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(10), 274; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100274
Received: 1 September 2020 / Revised: 22 September 2020 / Accepted: 23 September 2020 / Published: 25 September 2020
Vulvovaginal candidosis is a common disease, and various treatment strategies have emerged over the last few decades. Clotrimazole belongs to the drugs of choice for the treatment of vulvovaginal candidosis. Although available for almost 50 years, systematic reviews on the usefulness of topical clotrimazole across disease severity and populations affected are scarce. Thus, we conducted a systematic literature search in the PubMed and Embase databases to summarize the effectiveness and safety of topical clotrimazole in the treatment of uncomplicated (acute) and complicated vulvovaginal candidosis. In total, 37 randomized controlled studies in women suffering from vaginal yeast infections qualified for inclusion in our review. In women with uncomplicated vulvovaginal candidosis, single intravaginal doses of clotrimazole 500 mg vaginal tablets provided high cure rates and were as effective as oral azoles. A single dose of clotrimazole 500 mg was equipotent to multiple doses of lower dose strengths. Prolonged treatment regimens proved to be effective in severe and recurrent cases as well as in symptomatic pregnant women. It is therefore expected that in the general population, clotrimazole will continue to be widely used in the field of vaginal health in the upcoming years; more so as clotrimazole resistance in vaginal candidosis is rare. View Full-Text
Keywords: canesten; clotrimazole; vulvovaginal; vaginitis; mycosis; candidosis; yeast infection; candida; candida albicans; vaginal health canesten; clotrimazole; vulvovaginal; vaginitis; mycosis; candidosis; yeast infection; candida; candida albicans; vaginal health
MDPI and ACS Style

Mendling, W.; Atef El Shazly, M.; Zhang, L. Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience. Pharmaceuticals 2020, 13, 274. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100274

AMA Style

Mendling W, Atef El Shazly M, Zhang L. Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience. Pharmaceuticals. 2020; 13(10):274. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100274

Chicago/Turabian Style

Mendling, Werner, Maged Atef El Shazly, and Lei Zhang. 2020. "Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience" Pharmaceuticals 13, no. 10: 274. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100274

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop